Company intelligence / Profile preview

MYR Pharmaceuticals

Bad Homburg, Hesse, Germany

Ownership: Private
Employees: ~45
Development stage: Other

Overview

Hepcludex (bulevirtide) conditionally approved by EMA in July 2020 for chronic HDV in adults with compensated liver disease; Phase 2 data showed HDV RNA reduction in 60% of patients (≥2 log IU/mL); ongoing Phase 3 MYR301; US accelerated approval submission anticipated H2 2021.

Therapeutic areas: Infectious Diseases
Modalities: Peptide
Industry: Biotech

Beyond the preview

Go deeper on MYR Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MYR Pharmaceuticals.

Explore the full profile